Saturday 17 October 2026 Export MRKR’s income statement to Excel — free account

MARKER THERAPEUTICS, INC.

In the quarter to June 2026, revenue grew 2.75%, EPS grew 69.0% and free cash flow fell 97.8%, each against the same quarter a year earlier.

1.04 0.12 +13.04%

Follow MRKR

Alert me

Market cap: $15.3M
P/E: 0.0×
Fwd P/E: −1.5×
Dividend yield: —
F-score: 3/9
Altman Z: −28.68
Beneish M: −2.92
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 30.11%

Capital & Financial Ratios $m

Market Cap 15.34

Revenue 4.76

Net Income (8.71)

Free Cash Flow (9.76)

Net Debt (11.12)

Current Ratio 6.03

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E (1.47)

P/S ratio 4.22

P/B ratio 1.65

Past 5Y EPS Growth —

This Y EPS Growth 24.89%

Next Y EPS Growth (47.75%)

Next Y revenue growth 19.60%

Next 5Y EPS Growth 10.26%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.13%

10-year low 10-year high

P/B against its own 10 years 27.37%

10-year low 10-year high

EV/Sales against its own 10 years 25.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	15	19	17	12
Receivables	1	2	1	2
Inventory	—	—	—	—
Other	—	—	—	—
	17	22	19	15

	2023	2024	2025	Q'26
Payables	2	2	1	1
ST’ Debt	—	2	—	1
Other	—	—	—	—
	3	3	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	50.02%	0.31%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(9.29%)	(5.02%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	1	1	2	4
’24	1	1	2	2	7
’23	1	1	0	1	3
’22	1	1	1	1	4
’21	—	—	—	1	1
’20	—	0	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(4)	—	—	—
’25	(5)	(2)	(3)	(2)	(12)
’24	(4)	(4)	1	(5)	(11)
’23	(6)	(7)	(1)	(2)	(16)
’22	(12)	(1)	(8)	(6)	(27)
’21	(8)	(7)	(8)	(5)	(27)
’20	(4)	(4)	(6)	(6)	(20)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(4)	—	—	—
’25	(5)	(2)	(3)	(2)	(12)
’24	(4)	(4)	1	(5)	(11)
’23	(6)	(7)	(1)	(2)	(16)
’22	(15)	(3)	(12)	(11)	(32)
’21	(10)	(7)	(9)	(5)	(30)
’20	(4)	(8)	(7)	(10)	(29)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.16)	(0.09)	—	—	—
’25	(0.40)	(0.29)	(0.12)	(0.04)	(0.79)
’24	(0.27)	(0.25)	(0.26)	(0.42)	(1.19)
’23	(0.57)	0.29	(0.34)	(0.31)	(0.94)
’22	(1.20)	(1.10)	(0.80)	(0.46)	(3.58)
’21	(1.60)	(1.30)	(1.50)	(1.20)	(5.50)
’20	(1.40)	(1.40)	(1.60)	(1.80)	(6.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	33.20	26.00	25.80	26.10	13.20	9.00	2.20	0.67	2.44	0.81	Analyst estimates 2026–2028 Powerpack
	High	98.40	53.50	135.50	91.70	33.90	37.70	10.30	9.68	5.99	4.07
People
People	Employees	8	7	11	28	44	56	67	8	5	5
	Revenue/emp, $m	0.00	0.03	0.02	0.01	0.01	0.02	0.05	0.41	1.32	0.71
Income, $m
Income, $m	Revenue	—	0	0	0	0	1	4	3	7	4
	Gross margin, %	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(2)	(11)	(148)	(21)	(29)	(42)	(20)	(14)	(11)	(12)
	EBT margin, %	0.00	(5,997.92)	(71,824.22)	(10,050.66)	(6,149.55)	(3,372.71)	(562.85)	(424.09)	(162.06)	(343.38)
	Net income	(2)	(11)	(148)	(21)	(29)	(42)	(30)	(8)	(11)	(12)
	Depreciation	—	—	—	0	1	3	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.19	0.11	0.05	0.10	0.16	0.42	0.38	0.73	0.23
	Earnings	(3.60)	(11.60)	(77.50)	(4.70)	(6.10)	(5.50)	(3.58)	(0.94)	(1.19)	(0.79)
	Cash flow	(9.45)	(8.93)	(7.58)	(4.01)	(4.26)	(3.57)	(3.23)	(1.87)	(1.21)	(0.78)
	Capex	0.00	0.00	(0.08)	(0.08)	(1.97)	(0.41)	(0.59)	0.00	0.00	0.00
	Free cash flow	(9.45)	(8.93)	(7.66)	(4.09)	(6.23)	(3.97)	(3.82)	(1.87)	(1.21)	(0.78)
	Book value	8.98	3.87	31.08	9.67	5.81	5.75	2.35	1.60	2.07	1.10
	Shares, m	1	1	2	5	5	8	8	9	9	15
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	0.00	0.00	63.80	34.16	6.66	14.53	4.24	4.80
	P/B	—	10.52	1.79	2.98	2.49	1.65	1.19	3.42	1.50	1.36
	EV/Sales	—	0.00	0.00	0.00	44.19	14.01	3.47	10.16	1.58	1.57
	EV/FCF	—	(3.95)	(3.05)	(4.69)	(1.61)	(0.98)	(0.29)	(1.18)	(0.45)	(0.31)
Cash, $m
Cash, $m	Operating cash flow	(7)	(8)	(14)	(18)	(20)	(27)	(27)	(16)	(11)	(12)
	Capex	—	—	0	0	(9)	(3)	(5)	—	—	—
	Free cash flow	(7)	(8)	(15)	(19)	(29)	(30)	(32)	(16)	(11)	(12)
Balance, $m
Balance, $m	Working capital	6	4	59	43	18	33	9	14	19	17
	Total debt	0	—	—	0	0	1	1	—	2	—
	Net debt	(8)	(5)	(62)	(44)	(21)	(43)	(11)	(15)	(17)	(17)
	Shareholders’ equity	6	4	59	44	27	44	20	14	19	17
Returns, %
Returns, %	ROA	(33.71)	(167.64)	(439.54)	(39.50)	(62.42)	(73.63)	(58.37)	(31.96)	(54.82)	(59.20)
	ROIC	0.00	0.00	0.00	(3,644.97)	(282.93)	(2,225.27)	(147.32)	0.00	(645.52)	0.00
	ROE	32.36	(223.15)	(469.72)	(41.44)	(80.37)	(117.42)	(94.14)	(48.95)	(65.81)	(68.81)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PBM Psyence Biomedical Ltd.	$16.5M	0.2×	—	—	n/m	−707.20% (below 0%: shrinking)	—	0.00%	Compare
TCRX TScan Therapeutics, Inc.	$16.2M	— (loss-making)	— (loss-making)	−65.83% (below 0%: shrinking)	n/m	+18.95% (above 0%: growing)	100.00%	(2,901.33%)	Compare
AKTX Akari Therapeutics PLC	$15.5M	— (loss-making)	—	—	n/m	+4.51% (above 0%: growing)	0.00%	0.00%	Compare
VAXX Vaxxinity, Inc.	$15.5M	— (loss-making)	— (loss-making)	−100.23% (below 0%: shrinking)	n/m	+17.00% (above 0%: growing)	0.00%	0.00%	Compare
MRKR MARKER THERAPEUTICS, INC.	$15.3M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	−97.84% (below 0%: shrinking)	100.00%	0.00%
NCEL NewcelX Ltd.	$15.3M	— (loss-making)	—	—	n/m	−87.71% (below 0%: shrinking)	0.00%	—	Compare
GTBP GT Biopharma, Inc.	$15.2M	— (loss-making)	—	−100.00% (below 0%: shrinking)	n/m	−41.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DARE Dare Bioscience, Inc.	$14.6M	— (loss-making)	— (loss-making)	+984.43% (above 0%: growing)	n/m	−30.23% (below 0%: shrinking)	(70.56%)	(1,582.93%)	Compare
ADAPY Adaptimmune Therapeutics PLC	$14.6M	— (loss-making)	— (loss-making)	−89.33% (below 0%: shrinking)	n/m	−174.72% (below 0%: shrinking)	81.71%	(221.45%)	Compare
Median of peers	$15.4M	—	—	−89.33%	—	−35.78%	0.00%	0.00%

All 614 Biotechnology stocks →

MARKER THERAPEUTICS, INC. (MRKR) key facts

MARKER THERAPEUTICS, INC. (MRKR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MRKR traded at $1.04, a market capitalization of $15.3 million.
Return on equity was −68.8% and debt-to-equity 0.07.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −28.68 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.